OBJECTIVE:Patients with obsessive-compulsive disorder (OCD) often only partially respond to serotonin reuptake inhibitors (SRIs). In such cases, American Psychiatric Association practice guidelines suggest augmenting SRIs with cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP) or antipsychotic medication (i.e., risperidone). We examined moderators and predictors of these 2 augmentation strategies. METHOD: Data came from a randomized controlled trial that compared adding EX/RP or risperidone to SRIs in adults with OCD. Patients entered the study on a stable SRI dosage and were randomized to EX/RP (N = 40), risperidone (N = 40), or placebo (N = 20). Data were analyzed using multilevel modeling. RESULTS:Pretreatment OCD severity, age, and depression were significant moderators. Although OCD severity was unrelated to EX/RP response, individuals with more severe OCD had poorer outcomes and slower improvement with risperidone. Increasing age predicted better response to risperidone, but not EX/RP. Increased depression predicted poorer response to placebo, but not EX/RP or risperidone. Poorer functioning predicted worse outcome across all 3 conditions. Together, these moderators and predictor accounted for 33% of the variance in outcomes, above and beyond the 30.8% accounted for by treatment condition. CONCLUSIONS: SRI augmentation with EX/RP was more effective than risperidone across all of the demographic and clinical variables tested. EX/RP's superiority over risperidone increased with baseline OCD severity and with younger age. These data indicate that EX/RP should be the recommended SRI augmentation strategy, even for severe OCD. What determines the degree of EX/RP response in individual patients deserves further study. (c) 2015 APA, all rights reserved).
RCT Entities:
OBJECTIVE:Patients with obsessive-compulsive disorder (OCD) often only partially respond to serotonin reuptake inhibitors (SRIs). In such cases, American Psychiatric Association practice guidelines suggest augmenting SRIs with cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP) or antipsychotic medication (i.e., risperidone). We examined moderators and predictors of these 2 augmentation strategies. METHOD: Data came from a randomized controlled trial that compared adding EX/RP or risperidone to SRIs in adults with OCD. Patients entered the study on a stable SRI dosage and were randomized to EX/RP (N = 40), risperidone (N = 40), or placebo (N = 20). Data were analyzed using multilevel modeling. RESULTS: Pretreatment OCD severity, age, and depression were significant moderators. Although OCD severity was unrelated to EX/RP response, individuals with more severe OCD had poorer outcomes and slower improvement with risperidone. Increasing age predicted better response to risperidone, but not EX/RP. Increased depression predicted poorer response to placebo, but not EX/RP or risperidone. Poorer functioning predicted worse outcome across all 3 conditions. Together, these moderators and predictor accounted for 33% of the variance in outcomes, above and beyond the 30.8% accounted for by treatment condition. CONCLUSIONS:SRI augmentation with EX/RP was more effective than risperidone across all of the demographic and clinical variables tested. EX/RP's superiority over risperidone increased with baseline OCD severity and with younger age. These data indicate that EX/RP should be the recommended SRI augmentation strategy, even for severe OCD. What determines the degree of EX/RP response in individual patients deserves further study. (c) 2015 APA, all rights reserved).
Authors: Lorrin M Koran; Gregory L Hanna; Eric Hollander; Gerald Nestadt; Helen Blair Simpson Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: M H Bloch; A Landeros-Weisenberger; B Kelmendi; V Coric; M B Bracken; J F Leckman Journal: Mol Psychiatry Date: 2006-04-04 Impact factor: 15.992
Authors: Anthony Pinto; Jane L Eisen; Maria C Mancebo; Benjamin D Greenberg; Robert L Stout; Steven A Rasmussen Journal: Psychiatry Res Date: 2007-03-21 Impact factor: 3.222
Authors: Helen B Simpson; Edna B Foa; Michael G Wheaton; Thea Gallagher; Marina Gershkovich; Andrew B Schmidt; Jonathan D Huppert; Raphael B Campeas; Patricia A Imms; Shawn P Cahill; Christina DiChiara; Steven D Tsao; Anthony C Puliafico; Daniel Chazin; Anu Asnaani; Kelly Moore; Jeremy Tyler; Shari A Steinman; Arturo Sanchez-LaCay; Sandy Capaldi; Ivar Snorrason; Elizabeth Turk-Karan; Donna Vermes; Eyal Kalanthroff; Anthony Pinto; Chang-Gyu Hahn; Bin Xu; Page E Van Meter; Martha Katechis; Jennifer Scodes; Yuanjia Wang Journal: Behav Res Ther Date: 2021-05-29
Authors: María Alemany-Navarro; Javier Costas; Eva Real; Cinto Segalàs; Sara Bertolín; Laura Domènech; Raquel Rabionet; Ángel Carracedo; Jose M Menchón; Pino Alonso Journal: Transl Psychiatry Date: 2019-02-04 Impact factor: 6.222